Citigroup keeps Elan at sell

Elan Corp plc was rated continued at sell by Citigroup Investment Research analyst Andrew Swanson after Citigroup's physician experts voiced caution on the widespread commercial use of Tysabri. The physicians believe it would be prudent to contain Tysabri in clinical trials, due to questions about adequate monitoring. However, the physicians did not rule out the return of Tysabri to market, but expected a very limited opportunity for the product. Citi's rating is 3S, for sell and speculative. Shares of the Dublin, Ireland, pharmaceutical company were up $0.29, or 2.28%, at $12.99 on volume of 16,088,400 shares versus the three-month running average of 9,890,540 shares. (NYSE: ELN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.